Approved comparison material connected to this topic.
15 total recordsSource comparisons are presented without a generated winner.
Acute Neuroinflammation Research 4-6mg per injection 3x weekly (Mon/Wed/Fri) 2-3 weeks Best supported by published TBI and stroke models. Short cycles capture peak inflammatory window Peripheral Neuropathy Mod…
Before selecting a dosage protocol, researchers must align the dosing strategy with the biological endpoint, model system, and timeline constraints. The table below compares the most commonly referenced ARA-29…
Sarcoidosis-SFN Phase 2 4 3× weekly (SC) 28 days Neuropathic pain reduction (VAS) The Lancet 2014 Diabetic Neuropathy Phase 2 2 12 weeks IENFD improvement, corneal nerve density Diabetes Care 2015 Extended Neu…
Before selecting a dosing protocol, understanding how different regimens compare in efficacy, safety, and practical administration is essential. 2 mg subcutaneous 3x weekly for 4 weeks Inconsistent response; ~…
| Protocol Type | Dosage | Frequency | Duration | Injury Phase | Bottom Line ||—|—|—|—|—|| Acute Soft Tissue Injury | 6–8mg SC | 3× weekly | 4–6 weeks | Days 0–14 (inflammatory + early proliferative) | Front-l…
Sarcoidosis-associated SFN 4mg SC daily 28 days Inflammatory cytokine reduction (TNF-α, IL-6) via IRR signalling +0.73 fibers/mm IENFD; 29% pain score reduction Gold standard for inflammatory small fiber neuro…
Below is a synthesis of published dosing protocols from peer-reviewed neuroprotection studies, organized by research model and observed endpoint. Diabetic Polyneuropathy (Type 2 DM) 4 mg subcutaneous 3× weekly…
| Dose (mg) | Frequency | Duration | Target Inflammation Type | Biomarker Effect | Research Application | Professional Assessment ||—|—|—|—|—|—|| 2–3mg | Daily | 5–7 days | Mild acute inflammation (localized t…
Acute inflammation research protocols. Defined as inflammatory response initiated within 0–96 hours. Typically use ARA-290 at 4mg to 8mg subcutaneously once daily for 5–7 consecutive days. The rationale: acute…
This table shows calculated injection volumes for common ARA-290 vial sizes and target doses across standard bacteriostatic water volumes. 2mg 2mL 1,000mcg/mL 0.25mL 0.5mL 1.0mL 50 units 5mg 2,500mcg/mL 0.1mL …
4mg three times weekly Subcutaneous injection (Monday/Wednesday/Friday) Phase 2 RCT (ACTION trial, Diabetes Care 2015) 42% reduction in neuropathic pain; 1.8 fibers/mm² increase in corneal nerve density at 12 …
Acute Neuroprotection (Post-Injury) 4–6mg subcutaneous 3× weekly 4–8 weeks Stroke, traumatic brain injury, acute nerve damage Supported by ARISE trial data; aims to reduce inflammatory cascade during critical …
Sarcoidosis SFN (Annals of Neurology 2015) 4 3×/week SC Corneal nerve fiber density (CNFD) +1.2 fibers/mm² vs +0.1 placebo Proof-of-concept established; short duration limits long-term efficacy conclusions Dia…
This table compares the three most commonly used ARA-290 dosing protocols for tissue repair research, based on published pharmacokinetic data and receptor saturation studies. Each protocol represents a distinc…
Diabetic Neuropathy (Human Clinical) 4 mg Subcutaneous Daily Standard dose from Diabetes Care Phase II trial; 28-day protocols Acute Kidney Injury (Human Clinical) 2.4 mg/kg (168 mg for 70 kg) Intravenous infu…